Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmevid s.r.o., slovensko - sunitinib - 44 - cytostatica

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmevid s.r.o., slovensko - sunitinib - 44 - cytostatica

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmevid s.r.o., slovensko - sunitinib - 44 - cytostatica

Europese Unie - Slowaaks - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - sunitinib - 44 - cytostatica

Europese Unie - Slowaaks - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Europese Unie - Slowaaks - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karcinóm, obličková bunka - protein kinase inhibítory - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Europese Unie - Slowaaks - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - kolorektálne novotvary - antineoplastic agents, protein kinase inhibitors - stivarga je označené ako monotherapy na liečbu dospelých pacientov s metastatickým kolorektálnym (crc), ktorí boli v minulosti liečení, alebo nie sú považované za kandidátov na, k dispozícii terapie - tieto zahŕňajú fluoropyrimidine založené na chemoterapiu, anti-vegf terapia a anti-egfr terapia;unresectable alebo metastatickým gastrointestinálne stromal nádory (podstatu), ktorí postúpili na alebo netolerujú pred zaobchádzanie s imatinib a sunitinib;hepatocellular karcinóm (hcc), ktorí boli predtým liečení sorafenib.

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica